Lv11
50 积分 2020-11-01 加入
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis
1小时前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
1个月前
已完结
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
1个月前
已完结
Cyclophosphamide and Cyclosporin for GVHD Prevention
1个月前
已完结
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
2个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
2个月前
已完结
Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review
2个月前
已关闭
Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis
2个月前
已完结
AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children
2个月前
已完结
GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score–matched population-based cohort study
2个月前
已完结
皖公网安备34019202002308
